On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...